Ropinirole Tablets Recalled Due to Manufacturing Practice Deviations
Accord Healthcare is recalling 8,184 bottles of Ropinirole 4 mg tablets due to manufacturing practice deviations found during an FDA inspection. The recalled batches were distributed in the United States, Puerto Rico, and Canada.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is a Class II FDA recall based on manufacturing practice deviations identified during inspection. No illnesses or injuries have been reported. Per the rubric, when no illnesses/injuries are reported and the hazard is theoretical, the score is at most 3. The precautionary nature of this recall supports a Moderate rating.
Plain-English summary
Accord Healthcare, Inc. is recalling Ropinirole Tablets USP 4 mg due to Current Good Manufacturing Practice (CGMP) deviations identified during an FDA inspection. Approximately 8,184 bottles are affected by this recall.
The affected batches are: P2106136 (expiration date 8/31/2023), P2106813 and P2106814 (expiration date 9/30/2023), and P2202764 (expiration date 4/30/2024). These tablets were distributed throughout the United States, including Puerto Rico, and Canada.
Patients should check if their medication is part of this recall by comparing the batch number and expiration date on their bottle with the recalled batches listed above. Anyone who has a recalled batch should contact their healthcare provider or pharmacist for instructions.
Patients should not discontinue use of Ropinirole without consulting their healthcare provider, as abruptly stopping this prescription medication could have health consequences.
The recalled product
- Product
- ROPINIROLE (ROPINIROLE)
- Brand
- ROPINIROLE
- Manufacturer
- Accord Healthcare, Inc.
- Category
- Drug — Prescription Tablet
- Hazard
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (7)
- Batches: P2106136
- Exp. Date 8/31/2023
- P2106813
- P2106814
- Exp. Date 9/30/2023
- P2202764
- Exp. Date 4/30/2024
UPCs (1)
- 316729237017
Distribution
Distribution scope not specified by the agency.
Related recalls
Same brand · ROPINIROLE
- HighFDA Recalls Ropinirole 3mg Tablets due to CGMP Deviations
FDA (Drugs) · 2023-03-08
- ModerateRopinirole Tablets Recalled Due to Manufacturing Quality Violations
FDA (Drugs) · 2023-03-08
- ModerateRopinirole Tablets Recalled by Accord Healthcare Following FDA Inspection
FDA (Drugs) · 2023-03-08
- HighRopinirole tablets recalled due to manufacturing practice deviations
FDA (Drugs) · 2023-03-08
- HighRopinirole tablets recalled due to FDA manufacturing compliance deviations
FDA (Drugs) · 2023-03-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27